Cara Therapeutics Stock News

Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalysts to help unlock value.

Wall Street brokerages forecast that Cara Therapeutics, Inc. (NASDAQ:CARA) will post sales of $3.62 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Cara Therapeutics earnings, with the lowest sales estimate coming in at $150,000.00 and the highest estimate coming in at $8.60 million. Cara Therapeutics posted sales of []

KORSUVA receives TDAPA reimbursement beginning April 2022

Equities analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA) to report ($0.50) earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Cara Therapeutics earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.60). Cara Therapeutics posted earnings of $1.59 per share during the same quarter last year, which []

Wells Fargo & Company MN lifted its position in Cara Therapeutics, Inc. (NASDAQ:CARA) by 53.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 223,861 shares of the biopharmaceutical companys stock after purchasing an additional 78,284 shares during the quarter. Wells Fargo & []

Della Vite, the Prosecco brand founded by celebrity sisters Cara, Poppy and Chloe Delevingne, launches in the EU just months after the brands expansion into the US, rounding off 2021 with a bang. The post Della Vite reflects on a year of growth and maturation as it expands into EU territories appeared first on The Drinks Business .

In last trading session, Cara Therapeutics Inc. (NASDAQ:CARA) saw 0.5 million shares changing hands with its beta currently measuring 1.04. Companys recent per share price level of $12.31 trading at -$0.58 or -4.50% at ring of the bell on the day assigns it a market valuation of $670.16M. That closing price of CARAs stock is Cara Therapeutics Inc. (NASDAQ:CARA) Currently -140.86% Below Its 52-Week High But The Downside Potential May Surprise You Read More »

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RDHL, BYSI, ATIP, and CODX. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link….

Cara Diet Ampuh dan Cepat Full Power Method Continue reading on Medium »

Prudential Financial Inc. purchased a new position in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 46,650 shares of the biopharmaceutical companys stock, valued at approximately $666,000. Other large investors also recently bought and sold shares of the []

Equities research analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA) to post earnings of ($0.50) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cara Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.42). Cara Therapeutics posted earnings of […]

Cara Therapeutics Inc. (NASDAQ:CARA) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -0.74% to the previous days close as strong demand from buyers drove the stock to $13.34. Actively observing the price movement in the last trading, the stock closed the session at $13.44, falling within a range of $13.06 Thinking About Buying Cara Therapeutics Inc. Stock? Heres What You Need To Know. Read More »

Charles Schwab Investment Management Inc. boosted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 3.5% during the second quarter, Holdings Channel reports. The institutional investor owned 356,224 shares of the biopharmaceutical companys stock after acquiring an additional 12,078 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Cara Therapeutics were worth []

Charles Schwab Investment Management Inc. boosted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 3.5% during the second quarter, Holdings Channel reports. The institutional investor owned 356,224 shares of the biopharmaceutical companys stock after acquiring an additional 12,078 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Cara Therapeutics were worth []